hdm2

Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.

p53-HDM2-IN-1 is a potent inhibitor of the p53-HDM2 protein-protein interaction, with an inhibitory concentration (IC50) of 0.103 μM, and has significant applications in cancer research.

EAPB-0503, an imidazoquinoxaline derivative and an analog of Imiquimod, selectively reduces HDM2 expression and activates the p53 pathway in cells expressing NPM1c, thereby inducing apoptosis.

HLI373 is an efficacious Hdm2 inhibitor, an ubiquitin ligase (E3), effective in inducing apoptosis of several tumor cells sensitive to DNA-damaging agents [1], and also shows prominent antimalarial activity [2].

TDP665759 is an inhibitor of the Hdm2:p53 complex that acts by suppressing human tumor cell proliferation in vitro.

HLI98C is a HDM2 ubiquitin ligase inhibitor with anti-tumor activity.

HLI98D is a HDM2 ubiquitin ligase inhibitor with anti-tumor activity.

HLI98E is a HDM2 ubiquitin ligase inhibitor with anti-tumor activity.

HLI373 dihydrochloride is a potent Hdm2 inhibitor, efficiently restraining the ubiquitin ligase activity of Hdm2 and effectively prompting apoptosis in DNA-damaging agent-sensitive tumor cells[1]. Additionally, HLI373 dihydrochloride exhibits antimalarial activity[2].

SCH529074 is a selective activator of p53 (Ki = 1 μM) and can be used in studies about non-small-cell lung carcinoma. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53.

MK-4688 is a potent inhibitor of the HDM2-p53 protein-protein interaction.

MI-219 is a human double minute 2 (HDM2) inhibitor.

XL-188 is a highly potent and selective inhibitor of USP7. XL188 inhibited USP7 catalytic domain and full-length enzyme with IC50 values of 193 and 90 nM, respectively. XL188 Promotes USP7-Dependent Loss of HDM2 and Increase of p53 and p21. XL188 represents one of only a small set of mammalian DUB inhibitors with low nanomolar potency and a high degree of selectivity relative to other DUBs

HDM-201 succinate is an orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity.

NVP-CFC218 is a novel potent and selective p53-HDM2 inhibitor.